SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...
Health-evidence reviewers reverse recommendation on a blood test that detects a biomarker of a common cancer after decades of ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic ...
The Independent on MSN
New blood test could show if prostate cancer treatment is failing
New blood test could show if prostate cancer treatment is failing - The discovery could lead to personalised treatments for ...
Prostate-specific antigen (PSA) blood testing likely reduces the risk of death from prostate cancer, found a new review ...
The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT). (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that eight abstracts featuring data derived from testing with ...
Genomic profiling can help personalize cancer care, but patients may not be offered these tests due to a burdensome ...
PHILADELPHIA, PA – The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate ...
Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...
Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit ...
Researchers at Moffitt Cancer Center report encouraging early results from a phase 2 study examining whether immunotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results